Page 115 - Read Online

Hann et al. Urine markers for HCC monitoring

Figure 1: DNA biomarkers levels in serial urine samples from 10 patients. All patients were being monitored for HCC recurrence by MRI
and serum AFP. The urine samples were collected prospectively from HCC patients (when available) after curative treatment (indicated
by arrows) and at follow-up visits. Samples were retrospectively measured for HCC DNA biomarkers in a blinded fashion, with a follow-up
MRI diagnosis of whether or not recurrence was detected. Three DNA biomarker values (copies/mL urine), TP53 249T mutation (TP53m),
methylated RASSF1A (mRASSF1A) and methylated GSTP1 (mGSTP1), along with serum AFP (ng/mL serum), were plotted at office
visits until the last available visit in which an MRI was performed. The “Pos” represents detection of HCC recurrence by MRI and the “Neg”
represents no recurrence was detected by MRI at the time of the visit. HCC: hepatocellular carcinoma; MRI: magnetic resonance imaging;
AFP: alpha fetal protein
Hepatoma Research ¦ Volume 3 ¦ June 6, 2017 107